前列地尔联合贝那普利治疗糖尿病肾病蛋白尿的疗效探讨

目的探讨前列地尔联合贝那普利治疗糖尿病肾病蛋白尿的疗效。方法选取该院2012年1月—2015年11月收治的87例DN患者作为研究对象。按照入院顺序随机分为实验组和对照组,对照组患者采取贝那普利治疗,实验组患者在此基础上联合前列地尔治疗,观察患者临床疗效、治疗前和治疗8周后24 h尿蛋白含量、24 h尿微白蛋白排泄率、不良反应发生情况。结果实验组患者治疗总有效率和治疗显效率高于对照组,差异有统计学意义(P0.05),实验组患者治疗后8周24 h尿蛋白含量、24 h尿微白蛋白排泄率低于治疗前和对照组,差异有统计学意义(P0.05)。对照组患者治疗后8周24 h尿蛋白含量、24 h尿微白蛋白排泄率低于治疗前,差异有统计学意义(P0.05)。实验组患者和对照组患者不良反应比较,差异无统计学意义(P0.05)。结论前列地尔联合贝那普利治疗糖尿病肾病蛋白尿的效果较好,患者8周24 h尿蛋白含量、24h尿微白蛋白排泄率较低,临床应用价值较高。     

贝那普利联合前列地尔治疗糖尿病肾病蛋白尿的临床探析

目的探析贝那普利联合前列地尔治疗糖尿病肾病蛋白尿的临床效果。方法选取2013年5月—2014年5月间该院收治的糖尿病肾病蛋白尿患者52例,分为两组。对照组给予贝那普利口服治疗,观察组给予贝那普利与前列地尔联合治疗,对比两组治疗效果。结果观察组24 h尿蛋白含量与24 h尿微白蛋白排泄率降低明显,不良反应相对较少,两组治疗效果差异有统计学意义（P〈0.05）。结论糖尿病肾病蛋白尿应用贝那普利与前列地尔联合治疗能够显著减少尿蛋白含量,预防多种不良反应出现,改善患者依从性与生存质量,值得临床广泛应用。     

贝那普利联合前列地尔治疗糖尿病肾病蛋白尿的临床探析

目的探析贝那普利联合前列地尔治疗糖尿病肾病蛋白尿的临床效果。方法选取2013年5月—2014年5月间该院收治的糖尿病肾病蛋白尿患者52例,分为两组。对照组给予贝那普利口服治疗,观察组给予贝那普利与前列地尔联合治疗,对比两组治疗效果。结果观察组24 h尿蛋白含量与24 h尿微白蛋白排泄率降低明显,不良反应相对较少,两组治疗效果差异有统计学意义(P0.05)。结论糖尿病肾病蛋白尿应用贝那普利与前列地尔联合治疗能够显著减少尿蛋白含量,预防多种不良反应出现,改善患者依从性与生存质量,值得临床广泛应用。     

前列地尔联合贝那普利及黄葵胶囊治疗糖尿病肾病蛋白尿的疗效

目的观察前列地尔联合贝那普利及黄葵胶囊治疗糖尿病肾病蛋白尿的疗效。方法选择该院2016年2月—2017年2月期间诊疗的40例糖尿病肾病蛋白尿患者临床资料为研究对象,按照相应比例随机划为对照组20例、实验组20例。对照组患者采用贝那普利和黄葵胶囊治疗,实验组患者在此基础上联合前列地尔药物治疗,对比两组患者治疗总有效率、24 h尿蛋白含量和微白蛋白排泄率、不良反应。结果对照组治疗总有效率为65.00%,实验组治疗总有效率为95.00%,即两组患者治疗总有效率对比,差异有统计学意义(P0.05)。治疗前,两组患者24 h尿蛋白含量和微白蛋白排泄率对比,差异无统计学意义(P0.05);治疗后,实验组患者24 h尿蛋白含量和微白蛋白排泄率明显低于对照组,即两组患者24 h尿蛋白含量和微白蛋白排泄率对比中,差异有统计学意义(P0.05)。实验组患者不良反应为10.00%,对照组患者不良反应为50.00%,即两组患者不良反应对比,差异有统计学意义(P0.05)。结论相较于糖尿病肾病蛋白尿患者而言,前列地尔联合贝那普利及黄葵胶囊治疗手段的运用,可促进治疗总有效率的提升,降低患者24h尿蛋白含量和微白蛋白排泄率指标,且患者不良反应相对较低,值得推广。     

前列地尔联合贝那普利治疗糖尿病肾病蛋白尿临床研究

目的分析前列地尔联合贝那普利治疗糖尿病肾病蛋白尿的临床效果。方法选取84例糖尿病肾病患者,并随机分成对照组和观察组,对照组患者采取常规治疗,观察组患者采用前列地尔联合贝那普利治疗,一个月后,比较两组患者治疗前后的尿蛋白排泄情况,并分析两组患者的不良反应。结果经过一个月的治疗后,观察组与对照组相比,尿蛋白含量、尿微白蛋白含量减少的程度更加明显,差异有统计学意义(P0.05);两组都未出现严重不良反应。结论前列地尔联合贝那普利能够明显改善糖尿病肾病患者的尿蛋白水平,并安全有效的治疗糖尿病肾病,值得临床推广。     

前列地尔联合贝那普利治疗糖尿病肾病蛋白尿在临床应用中的效果

目的探讨前列地尔联合贝那普利对糖尿病肾病蛋白尿的治疗情况,并对其临床应用效果进行总结性分析。方法将泗洪县分金亭医院2012年10月—2014年9月收入的100例糖尿病肾病蛋白尿患者纳入本次研究,并随机平均分为两组,观察组和对照组,每组患者50例。对照组50例患者给予贝那普利进行治疗,观察组在应用贝那普利的基础上联合前列地尔进行治疗,两组患者均接受治疗三个月。比较两组患者24 h尿蛋白定量、尿微量白蛋白排泄率及不良反应的发生情况。结果治疗后观察组和对照组24 h尿蛋白定量和尿微量白蛋白排泄率均较治疗前降低,但观察组下降幅度明显高于对照组,且差异具有统计学意义(P0.05)。观察组不良反应发生率为10%,对照组不良反应发生率为8.33%,两组在不良反应发生率方面差异无统计学意义(P0.05)。结论前列地尔联合贝那普利对糖尿病肾病蛋白尿的治疗效果较好,可有效降低尿蛋白含量,且不良反应发生率低,安全性高,值得在临床上进行推广使用。     

前列地尔与贝那普利联合治疗糖尿病肾病蛋白尿的临床研究

目的探讨前列地尔与贝那普利联合治疗糖尿病肾病蛋白尿的效果。方法选取2015年3月—2017年3月该院收治的糖尿病肾病蛋白尿患者130例,随机分为2组各65例,观察组给予前列地尔联合贝那普利,对照组给予贝那普利,比较疗效。结果观察组总有效率为86.2%,明显优于对照组73.8%(P0.05);治疗后观察组24 h尿蛋白定量(153.8±10.4)mg/24 h、24 h尿微量白蛋白排泄率(2.35±0.33)mg/mol.Cr下降显著优于对照组(P0.05)。结论糖尿病肾病蛋白尿患者运用前列地尔与贝那普利联合治疗,能有效降低蛋白尿水平,改善肾功能,疗效显著。     

前列地尔联合贝那普利治疗糖尿病肾病蛋白尿的疗效

目的分析研究前列地尔联合贝那普利治疗糖尿病肾病蛋白尿的治疗效果。方法选取2015年3月—2016年3月在该院诊治的糖尿病肾病患者110例作为观察对象,根据不同的治疗方法将其分成对照组和观察组,每组55例;对照组患者予以常规治疗方法,观察组患者予以前列地尔联合贝那普利的治疗方法;治疗结束后,对两组患者的治疗效果进行对比分析。结果两组患者治疗后的24 h尿蛋白定量以及24 h尿微白蛋白排泄量均明显低于治疗前,而且观察组患者的改善效果比对照组更好,差异有统计学意义(P0.05);观察组患者的治疗有效率显著优于对照组患者,差异有统计学意义(P0.05);观察组患者的不良反应发生率明显低于对照组患者,差异有统计学意义(P0.05)。结论采用前列地尔联合贝那普利治疗糖尿病肾病蛋白尿,治疗效果确切,安全性高,对患者的尿蛋白水平有明显的改善作用,值得临床借鉴。     

前列地尔联合贝那普利治疗糖尿病肾病蛋白尿的临床效果观察

目的观察分析对糖尿病肾病蛋白尿患者在临床中行前列地尔与贝那普利进行联合治疗的效果。方法择取在2017年9月—2018年9月时段到该医院接受治疗的78例糖尿病肾病蛋白尿患者,将随机数字表法作为分组依据,分为参照组、实验组,39例/组,参照组接受常规治疗,实验组接受前列地尔与贝那普利联合治疗。统计、观察临床治疗效果以及治疗前后24 h尿蛋白定量、24 h尿微白蛋白排泄量、不良反应发生情况,并予以评价与对比分析。结果治疗前,组间对比24 h尿蛋白定量、24 h尿微白蛋白排泄量相近(P0.05);治疗后,实验组临床治疗效果以及24 h尿蛋白定量、24 h尿微白蛋白排泄量、不良反应发生情况均显著优于参照组(P0.05)。结论对于糖尿病肾病蛋白尿患者,应用前列地尔与贝那普利进行联合治疗后,能够改善蛋白尿情况,且不良反应发生率较低,可有效促进康复,在临床中具有进一步推广的应用价值。     

前列地尔联合贝那普利治疗糖尿病肾病蛋白尿的疗效

目的探究前列地尔联合贝那普利治疗糖尿病肾病蛋白尿的临床效果。方法资料随机选取2013年6月—2014年6月该院收治的135例糖尿病肾病患者,按随机数字表法分为研究组68例,对照组67例。对照组予以常规方法治疗,研究组在此基础上予以前列地尔联合贝那普利治疗,分析两组治疗效果。结果治疗后两组24 h尿蛋白定量、24 h尿微白蛋白排泄量均低于治疗前,且研究组显著低于对照组,治疗有效率95.59%高于对照组77.61%,不良反应发生率7.35%低于对照组23.88%,差异有统计学意义(P0.05)。结论前列地尔联合贝那普利治疗糖尿病肾病疗效确切,安全可行,可显著改善患者尿蛋白水平。     

肿瘤病人弓形虫感染分析

在肿瘤的发生和发展进程中 ,多伴有免疫功能低下或缺陷 ,从而极易遭受各种感染。弓形虫是机会感染因子 ,当患者免疫功能受损时 ,易于感染 ,还会使隐性感染激活 ,引起低热不退、淋巴结肿和脑神经系统的反应 ,此现象尚未引起临床医师的重视。近年来 ,我们对 4 0 9例肿瘤病人进行了弓形虫感染及弓形虫病的分析观察 ,报告如下 :1　材料与方法1 1　材料　 30 4例病人血清取自江西省肿瘤医院住院或门诊病人 ,随机抽样后低温保存待检 ,10 5例取自其他医院送检样品 ,有急性症状者随到随检 ,以便及时做病原学检测。1 2　弓形虫病诊断方法1 2 1　免疫…     

A patient with rectal ulcer with severe stenosis presenting with perforated peritonitis

We report a patient with rectal ulcer with severe stenosis, who underwent urgent surgical treatment for perforated peritonitis. The 54-year-old man suddenly developed cramping abdominal pain and fever while hospitalized, with signs of peritoneal irritation. An emergency laparotomy was performed, and severe stenosis of the rectum and a perforated lesion on the oral side approximately 10 cm distant from the stenosis were found, with massive abdominal purulent fluid. He was treated by rectosigmoid colon resection with transverse colon loop colostomy. Histopathologically, the stenosis was caused by ulceration extending to all muscular layers of the rectum, with inflammatory changes. Benign rectal stenosis is so rare that differential diagnosis from malignancy may be difficult when there are inflammatory changes in the surrounding tissues. However, it is necessary to keep in mind the likelihood of this disease in differentiation from rectal cancer. Received: December 21, 1998 / Accepted: May 28, 1999     

Infection with Rhodococcus equi in a patient with sarcoidosis treated with corticosteroids

A 51-year-old female farmer was diagnosed as having sarcoidosis. During 4 years of observation, slow radiological progression was observed. Cough then developed, necessitating treatment with corticosteroids. After 28 months of continuous treatment with prednisolone in low doses (5-7.5 mg daily), she suffered fever episodes, recurrent haemoptyses, general malaise and loss of weight. A chest roentgenogram showed a left upper lobe infiltrate, which progressed and finally cavitated, and rib destruction. Despite efforts, including a thoracotomy, 22 months passed before a diagnosis could be made. Blood and sputum cultures and cultures from the destroyed rib showed growth of Rhodococcus equi, a common soil organism which can cause infections in foals and other animals. Treatment with rifampicin and erythromycin was successful. R. equi has been reported to cause infection in patients with neoplastic disease and/or immunosuppression, but the disease might be more common than is suggested by the sparse case reports in the literature, owing to lack of familiarity with the organism, which will tend to be overlooked as a contaminant.     

Evaluation of atrial vulnerability with transoesophageal stimulation in patients with atrioventricular junctional: Comparison with patients with ventricular pre-excitation and with normal subjects

The aim of our work was to evaluate the inducibility of atrialfibrillation in a group of patients with atrioventricular junctionalreentrant tachycardia and to compare it with that of patientswith a Kent-type ventricular pre-excitation (Wolff-Parkinson-Whitesyndrome) and a control group. One hundred and twenty-five subjects were separated into groups.Group 1 comprised 49 Wolff-Parkinson-White patients, with amean age of 26.4, range 10.66 years; group 2, 51 patients withatrioventricular junctional reentrant tachycardia inducibleby transoesophageal atrial stimulation andlor clinically documented,with a mean age of 43.4, range 16–78 years; group 3, 25control subjects with a mean age of2.64, range 13–76 years. Each subject underwent atrial transoesophageal stimulation withthe following protocol: programmed atrial stimulation with 1and 2 stimuli during atrial pacing of 100. min^–1 and 150.min^–1; atrial stimulation for 10 s at a rate of 200–300–400–500–600.min^–1 with intervals of 10 s between stimulations, fivesuccessive ‘ramp-up’ atrial stimulations for 9 swith the rate increasing from 100 to 800. min^–1 with intervalsof 10 s between stimulations. The end point was the completionof the protocol or induction of sustained atrial fibrillation(>1 min). The chi-square test was used for statistical analysis. Our resultsshowed that in group 1 atrial fibrillation was induced in 27149patients (55.1%); this was sustained in 13149 (26.5%) and non-sustainedin 14149 (28.5%); in group 2, atrial fibrillation was inducedin 22151 patients (43.0%); it was sustained in 7151 (13.7%)and non-sustained in 15151 (29.4%); in group 3, sustained atrialfibrillation was not induced in any subject and in only onesubject was a non-sustained atrial fibrillation (4 s) induced. The chi-square test showed that group 2 vs group 1 were non-significant,while group 2 vs group 3 and group 1 vs group 3 were significant(P<0.003 and P<0.0007, respectively). Therefore group 2 patients showed a greater atrial vulnerabilityin comparison to the control subjects and a similar vulnerabilityto group 1 patients. It is possible that the greater atrialvulnerability in the patients of group 2 was due to the doublenodal pathway.     

Treating patients with lupus with B-cell depletion

A new era in the treatment of systemic lupus erythematosus has dawned with the increasing introduction of monoclonal antibodies and other approaches, that target the key molecules involved in the pathogenesis of the disease. At present the ability to block the CD20 molecule on those B cells that carry this marker has proved the most effective way to treat patients resistant to conventional immunosuppressive drugs. However, these studies have all been open label and the results of double blind controlled studies are eagerly awaited.